Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists
References (42)
- et al.
Heroin reward is dependent on a dopaminergic substrate
Life Sci.
(1981) - et al.
Neural substrates of opiate reinforcement
Prog. Neuro-Psychopharmacol. Biol. Psychiat.
(1983) - et al.
Antagonism of the hyperactivity in dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine
European J. Pharmacol.
(1976) - et al.
Opposing effects of D-1 and D-2 receptor antagonists on acetylcholine levels un the rat striatum
European J. Pharmacol.
(1986) - et al.
Catecholamine systems as the neural substrate for intracranial self-stimulation: a hypothesis
Brain Res.
(1974) - et al.
[3H]Receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain
European J. Pharmacol.
(1984) SCH 23390 the first selective dopamine D-1 antagonist
European J. Pharmacol.
(1983)- et al.
Blockade of D-1 receptors by SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning
European J. Pharmacol.
(1987) - et al.
Neuroleptics block the positive reinforcing effects of amphetamine but not of morphine as measured by place preference conditioning
Pharmacol. Biochem. Behav.
(1985) - et al.
D2 dopamine receptors associated with inhibition of dopamine release from rat neostriatum are independent of cyclic AMP
Neurosci. Lett.
(1986)
Dopaminergic substrates of cocaine-induced place conditioning
Brain Res.
The pharmacology of sulpiride — a dopamine receptor antagonist
Gen. Pharmacol.
Selective blockade of dopamine D-1 receptors by SCH 23390 discloses striatal dopamine D-2 receptors mediating the inhibition of adenylate cyclase in rats
European J. Pharmacol.
Noradrenaline, dopamine and brain stimulation reward
Pharmacol. Biochem. Behav.
Place preference conditioning reveals the involvement of D-1 dopamine receptors in the motivational properties of μ- and κ-opioid agonists
Brain Res.
Dopaminergic Ergot Derivatives and Motor Function
Motivational effects of opioids: evidence on the role of endorphins in mediating reward or aversion
Pharmacol. Biochem. Behav.
Catecholamine theories of reward: a critical review
Brain Res.
Actions of drugs of abuse on brain reward systems; an update with specific attention to opiates
Pharmacol. Biochem. Behav.
Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SKF 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats
Psychopharmacology
Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum
Life Sci.
Cited by (144)
Behavioral assays of pain in rodent models of spinal cord injury
2022, Spinal Cord Injury PainInteractions between opioids and stimulants: Behavioral pharmacology of abuse-related effects
2022, Advances in PharmacologyDopaminergic cellular and circuit contributions to kappa opioid receptor mediated aversion
2019, Neurochemistry InternationalInvolvement of D1- and D2-like dopamine receptors in the dentate gyrus in the acquisition, expression, and extinction of the morphine-induced conditioned place preference in rats
2018, Behavioural Brain ResearchCitation Excerpt :Nevertheless, some other reports are inconsistent with the effects of these receptors on the rewarding effects of opioids. For instance, Shippenberg and Herz (1988) demonstrated that chronic intra-peritoneal infusion of SCH23390 during the conditioning phase terminated the reinforcing effect of morphine, but D2 antagonists (sulpiride and spiperone) were ineffective in modifying the motivational properties of opioid agonists [44]. Moreover, a report showed that the systemic administration of SCH23390 produced a dose-dependent conditioned aversion for the drug-associated place, but the injection of D2 antagonists (spiperone and sulpiride) was without effect [45].
The role of the vasopressin system and dopamine D1 receptors in the effects of social housing condition on morphine reward
2018, Drug and Alcohol DependenceCitation Excerpt :The mesolimbic dopaminergic system is involved in the rewarding and reinforcing properties of opioids and other drugs of abuse. Antagonism of D1 dopamine receptors (D1DRs) in the striatum decreases acquisition of morphine CPP (Shippenberg et al., 1993; Shippenberg and Herz, 1988), including after single-trial CPP acquisition (Fenu et al., 2006). Also, D1DR-null mutant mice do not develop locomotor sensitization to morphine (Becker et al., 2001), and do not acquire morphine CPP (Wang et al., 2015).